Article
Pharmacology & Pharmacy
Xiaoyu Wang, Zhe Wang, Xiaoyu Fan, Mingrui Yan, Lili Jiang, Yangliu Xia, Jun Cao, Yong Liu
Summary: Ibrutinib demonstrated strong inhibition on UGT enzymes, especially UGT1A1, UGT1A3, and UGT1A7, suggesting a potential risk for drug-drug interactions. In contrast, acalabrutinib exhibited weak inhibition on UGT enzymes, indicating a lower risk for causing clinically significant UGT-mediated DDIs.
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jiri Vrba, Barbora Papouskova, Katerina Lnenickova, Pavel Kosina, Vladimir Kren, Jitka Ulrichova
Summary: 2,3-Dehydrosilybin A and B are preferentially metabolized through conjugation reactions, with several human UGT and SULT enzymes potentially playing a role in these conjugations.
Article
Food Science & Technology
Ren-Jong Liang, Shu-Hao Hsu, Tien-Yu Chang, Tzu-Yi Chiang, Hong-Jaan Wang, Yune-Fang Ueng
Summary: Herb-drug interactions have become increasingly important in modern healthcare, especially in the treatment of cardiovascular disease. This review summarizes 55 herb-drug interactions and discusses their potential mechanisms. Due to the complexity of traditional Chinese medicines, a better understanding and management of these interactions is needed.
JOURNAL OF FOOD AND DRUG ANALYSIS
(2022)
Review
Pharmacology & Pharmacy
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland, Robyn Meech
Summary: Drug-drug interactions (DDIs) involving glucuronidated drugs have been historically overlooked but are clinically significant and can result in altered exposure of these drugs. This review examines the mechanisms, scope, and aetiology of these DDIs, including the inhibition and induction of UDPglucuronosyltransferase (UGT) enzymes and the potential involvement of drug transporters. It highlights the common occurrence and importance of UGT induction as a DDI mechanism and the need for dose individualisation due to clinically relevant DDIs. Comprehensive reaction phenotyping studies and rigorous assessment of new chemical entities with significant glucuronidation are recommended for early-stage drug development.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Toxicology
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yaqin Jia, Yuyi Feng, Lili Jiang, Yangliu Xia, Jun Cao, Yong Liu
Summary: Osimertinib demonstrates high inhibitory effects on human UDP-glucosyltransferases (UGTs) and human liver microsomes (HLMs), especially competitive inhibition against UGT1A1. At a dose of 80 mg/day, osimertinib shows a low risk of interaction via liver metabolism but a potential risk of interaction in the intestine.
TOXICOLOGY LETTERS
(2021)
Article
Pharmacology & Pharmacy
Liangliang He, Chunxia Xu, Ziying Wang, Shuyi Duan, Jinjin Xu, Chuan Li, Xinsheng Yao, Frank J. Gonzalez, Zifei Qin, Zhihong Yao
Summary: The study aimed to identify bioactive compounds from Xian-Ling-Gu-Bao capsule against estrogen glucuronidation. It found potent inhibitors for UGT1A10, 1A1, and 2B7, laying an important foundation for the pharmacodynamic material basis of XLGB. Six compounds demonstrated potent inhibitory effects against these three active enzymes, indicating their potential as natural inhibitors of estrogen glucuronidation.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xin Lv, Zhe Wang, Zhen Wang, Hang Yin, Yangliu Xia, Lili Jiang, Yong Liu
Summary: Ripretinib is the first FDA-approved fourth-line therapy for advanced gastrointestinal stromal tumor (GIST). It has been shown to inhibit the activity of several UDP-glucosyltransferase (UGTs) enzymes. However, its effects on different UGT isoforms and potential drug-drug interactions (DDIs) are still unclear.
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2023)
Article
Integrative & Complementary Medicine
Dai-yan Zhang, Wen-qing Cui, Ling Hou, Jing Yang, Li-yang Lyu, Ze-yu Wang, Ke-Gang Linghu, Wen-bin He, Hua Yu, Yuan-jia Hu
Summary: This study aims to expand potential targets and verify drug-herb interactions using the node2vec algorithm. The results show that node2vec algorithm performs the best among all algorithms and successfully identifies potential interactions between 32 herbal chemicals and drug targets.
Article
Oncology
Dong Gui Hu, Shashikanth Marri, Julie-Ann Hulin, Ross A. McKinnon, Peter Mackenzie, Robyn Meech
Summary: The UDP-glycosyltransferase (UGT) superfamily plays a critical role in the metabolism of anticancer drugs and pro/anti-cancer molecules. A comprehensive analysis of 10,069 tumors from 33 different types of cancers revealed widespread somatic mutations in UGT genes, which may impact the ability of cancer cells to metabolize drugs and endobiotics involved in cancer signaling pathways.
Article
Toxicology
Kouji Tagawa, Yoshihiro Maruo, Yu Mimura, Shinichi Ikushiro
Summary: The adverse effects of irinotecan are associated with genetic variants of UGT1As, which are enzymes that metabolize the drug. UGT1A1 and UGT1A6-UGT1A10 showed SN-38 glucuronidation activity, with UGT1A1 being the most active. Variants of these isoforms resulted in decreased glucuronidation activity. This study provides insights into the relationship between UGT1A variants and the level of glucuronidation, allowing for potential toxicity prediction before irinotecan treatment.
TOXICOLOGY MECHANISMS AND METHODS
(2023)
Review
Pharmacology & Pharmacy
Dallas J. J. Smith, Huichang Bi, Josias Hamman, Xiaochao Ma, Constance Mitchell, Kumbukani Nyirenda, Tsitsi Monera-Penduka, Hellen Oketch-Rabah, Mary F. F. Paine, Syril Pettit, Wihan Pheiffer, Richard B. B. Van Breemen, Michelle Embry
Summary: The COVID-19 pandemic has led to the development of new anti-viral drugs that effectively reduce fatality and hospitalization rates in high-risk COVID-19 patients. Currently, nirmatrelvir/ritonavir (Paxlovid (TM)) combination is recommended for COVID-19 treatment. However, the ritonavir component interacts with CYP3A, which raises concerns about potential interactions with other drugs metabolized by CYP3A.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Sangeeta Shrestha Sharma, Shishir Sharma, Jie Zhao, Matthias Bureik
Summary: Cytochromes P450 (CYPs) and UDP-glucuronosyltransferases (UGTs) are important human drug metabolizing enzymes, and this study explores their mutual interactions. The study used recombinant co-expression of 19 human UGTs with CYP enzymes in yeast and found that UGT co-expression had a significant effect on P450 activity in most cases. The study also observed varying degrees of influence of CYP co-expression on UGT activity.
Article
Pharmacology & Pharmacy
Qi-Hang Zhou, Guang-Hao Zhu, Yun-Qing Song, Yuan-Fang Que, Qing-Qing He, Dong-Zhu Tu, Hai-Rong Zeng, Wei-Wei Qin, Chun-Zhi Ai, Guang-Bo Ge
Summary: Recent studies have shown that Methylophiopogonanone A (MOA) can inhibit various human UDP-glucuronosyltransferases (hUGTs), including UGT1A1, and exhibit strong inhibitory effects in different biological settings. The competitive inhibition of UGT1A1-catalysed reactions by MOA suggests potential interactions between MOA and human drug-metabolizing enzymes.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2021)
Article
Toxicology
Che -Fu Chang, Yu-Ching Chang, Jing-Tang Lin, Chen-Wei Yu, Yu-Ting Kao
Summary: UGTs in the gastrointestinal tract play a crucial role in protecting the body against toxic xenobiotics. This study examined the metabolism of raloxifene in differentiated Caco-2 monolayers by inducing the expression of UGT1A8 and UGT1A10 in these cells. The results suggest that salvigenin may enhance the pharmacological effects of UGT substrate drugs.
TOXICOLOGY IN VITRO
(2021)
Article
Toxicology
Xiaoyu Wang, Zhe Wang, Zhen Wang, Xiuyuan Chen, Hang Yin, Lili Jiang, Jun Cao, Yong Liu
Summary: Belinostat is a pan-HDAC inhibitor approved for PTCL treatment, showing inhibition on UGTs activities, particularly UGT1A3 and UGT1A1, leading to potential DDIs. Intravenous infusion of Belinostat may significantly increase AUC of co-administered drugs primarily cleared by UGT1A3 or UGT1A1, while oral administration of Belinostat is unlikely to cause significant DDIs through glucuronidation inhibition.
TOXICOLOGY LETTERS
(2021)
